Timolol external preparation for treating hemangioma

Abstract

The invention discloses a timolol external preparation for treating hemangioma. The prepared external preparation is ointment or gel prepared in the mode that two active ingredients including timolol and oleum menthae are added into a gel matrix or an ointment matrix, wherein the content of the timolol, by mass, accounts for 0.25-1% of the ointment or the gel, and the content of the oleum menthae, by mass, accounts for 1% of the ointment or the gel. The preparation method comprises the steps that timolol is prepared into a timolol saline solution in a salifying mode, the active ingredient oleum menthae is added into the timolol saline solution, the obtained solution is dispersed into the gel matrix according to the weight ratio of (1:1)-(1:10) to be subjected to swelling, and the gel is obtained; or the obtained solution is dispersed into the ointment matrix according to the weight ratio of (2.5:1)-(3:1), and the ointment is obtained. The preparation process is simple, easy to practice and applicable to requirements of industrial mass production. Pharmacodynamics results prove that the effective ingredients timolol and oleum menthae in the external preparation have the synergism for treating hemangioma and good tolerance, and no adverse reaction occurs.

Description

technical field [0001] The invention relates to the field of pharmaceutical preparations, in particular to an external timolol preparation for treating hemangioma and a preparation method thereof. Background technique [0002] Infantile hemangioma is the most common benign tumor in infants and young children, with an incidence rate as high as 10% and a tendency to increase year by year. More than 60% occur on the face and head and neck. Prematurity and low birth weight (<1500g) are possible predisposing factors, as is the use of progesterone during pregnancy. Clinically, it presents as erythematous patches of telangiectasia, papules, hypertrophic plaques, and masses. Although hemangiomas can regress on their own, some children still have serious complications such as ulcers, infections, pain, and even blindness and suffocation. [0003] After the β-receptor blocker propranolol was used to treat infantile hemangioma, it quickly became the first-line drug, but with a lar...

AI Technical Summary

Problems solved by technology

However, the solution is volatile and has a short action time. When it is applied to the lesions around the mouth and eyes, it is easy to flow into the eyes and cause systemic adverse reactions.

Images